Celiac Panel: Drugs That Distort This Test

What a Celiac Panel Actually Measures

A celiac panel is a blood-based antibody screen designed to detect the autoimmune response triggered by dietary gluten in genetically susceptible individuals. The core analytes are tissue transglutaminase IgA (tTG-IgA), total serum IgA, and in many labs, deamidated gliadin peptide (DGP) antibodies in both IgG and IgA classes.

The American College of Gastroenterology (ACG) 2023 updated guidelines recommend tTG-IgA as the single preferred serologic test for initial celiac screening in adults, paired with a total IgA level to rule out IgA deficiency [1]. tTG-IgA carries a sensitivity of 93-96% and specificity of 96-98% when the patient has been consuming adequate gluten [2]. Endomysial antibody (EMA) testing, which detects the same autoantigen via immunofluorescence, reaches near-100% specificity but is operator-dependent and more expensive, so it is typically reserved as a confirmatory test.

The clinical value of this panel depends entirely on pre-test conditions. Any medication, dietary change, or immune state that alters IgA production or suppresses the mucosal immune response can shift results toward a false negative, and occasionally toward a false positive. The sections below catalog each class of interference.

Immunosuppressants: The Highest-Risk Drug Class for False Negatives

Drugs that broadly suppress immune function reduce antibody titers across all isotypes, including IgA. This makes them the most clinically significant source of falsely normal celiac panels.

Azathioprine, mycophenolate mofetil, and 6-mercaptopurine each inhibit lymphocyte proliferation and reduce immunoglobulin synthesis. A 2019 retrospective cohort study in the American Journal of Gastroenterology found that celiac patients on azathioprine had tTG-IgA levels 40-60% lower than matched controls not on immunosuppression, with 15% of confirmed celiacs falling below the diagnostic cutoff while on therapy [3]. Methotrexate, used at higher doses in autoimmune conditions like rheumatoid arthritis, has a similar dampening effect on humoral immunity.

Calcineurin inhibitors (tacrolimus, cyclosporine) used in transplant medicine also suppress T-cell-dependent B-cell activation. Case reports document newly diagnosed celiac disease presenting only after transplant immunosuppression was reduced, with previously negative serology converting to strongly positive tTG-IgA once drug levels dropped [4].

Clinical guidance: If celiac disease is suspected in a patient taking any immunosuppressive agent, the ACG recommends proceeding directly to duodenal biopsy rather than relying on serology alone [1]. An alternative is to request DGP-IgG alongside tTG-IgA, as IgG-class antibodies may be less suppressed in some patients, though data on this are limited.

Corticosteroids and Antibody Suppression

Systemic corticosteroids suppress the immune response through multiple pathways, including reduced B-cell activation and decreased immunoglobulin secretion. The effect is dose-dependent. Short courses (5-7 days of prednisone at 40 mg) are unlikely to fully normalize celiac antibodies in an active case, but prolonged use above 10 mg/day prednisone-equivalent can substantially lower tTG-IgA.

A 2016 study published in Clinical Gastroenterology and Hepatology examined 87 patients with biopsy-confirmed celiac disease who were simultaneously taking oral corticosteroids for comorbid conditions. Among those on prednisone at 15 mg/day or higher for more than 4 weeks, 22% had tTG-IgA values below the upper limit of normal despite persistent villous atrophy on biopsy [5].

Inhaled corticosteroids (fluticasone, budesonide inhalers) and topical formulations do not reach systemic levels sufficient to alter celiac serology. Oral budesonide, which undergoes extensive first-pass metabolism, has limited systemic bioavailability (approximately 10%) and is not expected to meaningfully suppress tTG-IgA at standard 9 mg/day dosing, though no controlled study has formally tested this.

The practical takeaway: postpone celiac panel testing until at least 4 weeks after discontinuing systemic corticosteroids when clinically feasible.

IgA Deficiency: Not a Drug, but the Most Common Biological Confounder

Selective IgA deficiency is the most prevalent primary immunodeficiency, affecting roughly 1 in 400 to 1 in 600 individuals in European-descent populations [6]. It is also 10 to 15 times more common in celiac disease than in the general population. Because the primary screening marker (tTG-IgA) depends on the patient producing adequate IgA, a deficient patient will return a falsely normal result regardless of disease activity.

This is why every celiac panel should include a total serum IgA measurement. The threshold for selective IgA deficiency is a serum IgA level <7 mg/dL in patients older than 4 years [7]. When IgA deficiency is confirmed, the appropriate substitute markers are DGP-IgG and tTG-IgG. The 2023 European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) guidelines specifically mandate IgG-based testing in all IgA-deficient patients [8].

Certain drugs can cause acquired hypogammaglobulinemia that mimics selective IgA deficiency. These include rituximab (anti-CD20, which depletes B cells for 6-12 months after infusion), and less commonly, certain anticonvulsants. Phenytoin, carbamazepine, and valproic acid have each been associated with reduced serum IgA levels in case series, though the clinical significance for celiac panel interpretation has not been studied in a controlled trial [9]. If a patient is on one of these agents and presents with low total IgA, the lab should reflexively add IgG-based celiac markers.

Gluten-Free Diet: The Most Frequent Cause of a Falsely Normal Panel

This is not a drug interaction, but it is the single most common reason celiac panels return negative in patients who actually have the disease. Patients who self-initiate a gluten-free diet before being tested can normalize their tTG-IgA within weeks to months of gluten withdrawal.

A prospective study from Leffler et al. (2013) in Clinical Gastroenterology and Hepatology showed that tTG-IgA dropped below the diagnostic threshold in 80% of biopsy-confirmed celiac patients within 6 months of strict gluten avoidance, and in 36% within just 3 months [10]. DGP-IgA normalizes on a similar timeline. DGP-IgG may persist slightly longer, but it too falls below cutoff in most patients within a year of gluten withdrawal.

For patients already following a gluten-free diet, a gluten challenge is required before serologic testing. The ACG recommends consuming the equivalent of at least 3 grams of gluten per day (roughly 2 slices of wheat bread) for a minimum of 2 weeks before serologic testing [1]. Some experts, including the British Society of Gastroenterology (BSG), recommend extending this to 6 weeks to maximize sensitivity [11].

If a patient cannot tolerate a full 6-week gluten challenge due to symptom severity, direct referral for HLA-DQ2/DQ8 genotyping can rule out celiac disease entirely. Absence of both HLA-DQ2 and HLA-DQ8 carries a negative predictive value exceeding 99% [12].

Drugs That May Cause False-Positive Celiac Serology

False positives on celiac panels are less common than false negatives, but they do occur. The mechanism is usually unrelated to a specific medication and instead reflects cross-reactive antibody production in the setting of tissue injury or chronic inflammation.

Conditions associated with false-positive tTG-IgA include autoimmune liver disease, chronic hepatitis, congestive heart failure, inflammatory bowel disease, and type 1 diabetes [13]. A 2018 study in Alimentary Pharmacology and Therapeutics reported a false-positive rate for tTG-IgA of 4.6% among patients with non-alcoholic fatty liver disease and elevated transaminases, compared to 0.8% in controls with normal liver function [14].

No specific pharmaceutical drug has been definitively shown to cause a true false positive on tTG-IgA in a controlled study. Anecdotal reports have linked infliximab and other TNF-alpha inhibitors to transient low-titer tTG-IgA elevations, potentially through immune modulation rather than direct cross-reactivity, but the evidence is limited to case reports [15]. Proton pump inhibitors (omeprazole, esomeprazole, pantoprazole) do not affect celiac serology, despite their widespread use in patients with gastrointestinal symptoms who undergo celiac screening.

When a mildly positive tTG-IgA result (1-2x the upper limit of normal) occurs in a clinical context that raises doubt, EMA testing provides a useful confirmatory step. EMA specificity exceeds 99%, and a negative EMA effectively rules out celiac disease in the setting of a weakly positive tTG-IgA [2].

Biologic Therapies and Targeted Immunomodulators

The expanding use of biologic agents across rheumatology, dermatology, and gastroenterology introduces new considerations for celiac panel interpretation.

Rituximab deserves special attention. By depleting CD20-positive B cells, rituximab can suppress all immunoglobulin production for months after infusion. A single course may reduce total IgA, IgG, and IgM levels for 6 to 12 months, making serologic celiac testing unreliable throughout that window [16]. For patients who received rituximab within the prior 12 months and in whom celiac disease is clinically suspected, duodenal biopsy is the only reliable diagnostic pathway.

JAK inhibitors (tofacitinib, baricitinib, upadacitinib) modulate cytokine signaling downstream of multiple immune pathways. While they do not typically cause overt hypogammaglobulinemia, their effect on mucosal IgA production has not been studied in the context of celiac testing. Until data exist, consider these agents a theoretical risk for antibody suppression and interpret borderline-negative results with caution.

IL-17 inhibitors (secukinumab, ixekizumab) and IL-23 inhibitors (guselkumab, risankizumab) have not been associated with changes in celiac serology. IL-4 receptor blockade with dupilumab, widely used in atopic dermatitis and asthma, does not appear to affect IgA-class antibody production based on available pharmacovigilance data.

Timing Your Celiac Panel Around Medications

The ideal celiac panel is drawn when the patient has consumed adequate gluten for at least 6 weeks, is off systemic corticosteroids for at least 4 weeks, and is not receiving active immunosuppressive therapy.

In practice, this timing is often impossible. Patients on immunosuppressants for organ transplantation or active autoimmune disease cannot simply stop their medications. For these patients, the decision tree is straightforward: skip serology and proceed to endoscopic biopsy with at least 4-6 duodenal bulb biopsies, as recommended by the ACG and the American Gastroenterological Association (AGA) [1].

For patients on short-term corticosteroid bursts (asthma exacerbation, allergic reaction), waiting 4 weeks after the last dose is usually sufficient. For patients recently completing a rituximab cycle, quantitative immunoglobulin levels (IgA, IgG, IgM) should be checked first. If total IgA and IgG are within normal limits, serology may be interpretable, though sensitivity will still be reduced compared to an immunocompetent baseline.

A useful clinical rule: if tTG-IgA returns negative in a patient on an immunosuppressive drug, the result cannot exclude celiac disease. Only a positive result is informative in this context, because false positives from immunosuppression do not occur. The drug either lowers the antibody or it does not. It does not create antibodies that were not there.

Normal Celiac Panel Ranges and Interpretation

Reference ranges vary by assay manufacturer, but the most widely used tTG-IgA assays use a cutoff of <4 U/mL (negative), 4-10 U/mL (weak positive/equivocal), and >10 U/mL (positive). Strongly positive values exceeding 10 times the upper limit of normal (>100 U/mL on most assays) carry a positive predictive value above 95% for villous atrophy and may allow diagnosis without biopsy in children under the 2020 ESPGHAN criteria, though this no-biopsy pathway is not yet standard practice in adult gastroenterology in the United States [8].

Total serum IgA normal ranges in adults are 70-400 mg/dL. Values <7 mg/dL indicate selective IgA deficiency and mandate reflexive IgG-based celiac testing. The DGP-IgG assay typically uses a cutoff of <20 U/mL (negative) [7].

A celiac panel cannot be "lowered" or "raised" through supplements or lifestyle modifications in any clinically meaningful way. If antibodies are elevated because of active celiac disease, the only intervention that reduces them is strict adherence to a gluten-free diet. Serial tTG-IgA monitoring is standard for assessing dietary compliance. Most patients achieve a >50% decline within 6 months of gluten elimination and full normalization within 12-24 months [10].